3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Other hematologic neoplasm
1
Conditions
Neoplasms
4
Leukemia, Myeloid, Acute
3
Carcinoma
3
Small Cell Lung Carcinoma
1
Sarcoma, Myeloid
1
Myelodysplastic Syndromes
1
Leukemia
1
Hematologic Diseases
1
Carcinoma, Small Cell
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Non-Small-Cell Lung
1
Adenocarcinoma
1
Acute Disease
1
Interventions
Cytarabine
3
Cyclophosphamide
3
thymoglobulin
2
fludarabine phosphate
2
fludarabine
2
Thiotepa
2
Tacrolimus
2
Rituximab
2
Melphalan
2
Granulocyte Colony-Stimulating Factor
2
Filgrastim
2
vosaroxin
1
plerixafor
1
devimistat
1
blinatumomab
1
aldesleukin
1
Transplantation
1
Sirolimus
1
Razoxane
1
Mycophenolic Acid
1
Metformin
1
Mesna
1
Interleukin-2
1
Idarubicin
1
Gemtuzumab
1
Dexrazoxane
1
Clofarabine
1
Cladribine
1
Busulfan
1
Blood Specimen Collection
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Sarcoma, Myeloid
×
vosaroxin
×
Clear all
NCT02658487
2025-04-15
VITAL
Vanderbilt-Ingram Cancer Center
Phase 2
Completed
42 enrolled
12 charts